Posted by Michael Wonder on 21 Apr 2018
Indivior announces new drug submission to Health Canada for Sublocade (buprenorphine extended-release) injection for the treatment of moderate to severe opioid use disorder
20 April 2018 - Health Canada grants priority review designation for Sublocade.
Indivior today announced that it has filed a new drug submission with Health Canada’s Therapeutic Drugs Directorate for Sublocade (buprenorphine extended-release) injection, for subcutaneous use, for the treatment of moderate to severe opioid use disorder as part of a complete treatment plan to include counselling and psychosocial support. Health Canada granted Priority Review status for Sublocade on April 6, 20181. If approved, Sublocade will be marketed by Indivior Canada Ltd.
The submission of Sublocade to Health Canada follows approval of the drug by the U.S. FDA on 30 November 2017.
